Skip to main content

Market Overview

Wall Street Comfortable With Covidien Buy; Some See Move By Johnson & Johnson

Share:

Wall Street appeared comfortable with the latest big healthcare merger, this one the acquisition of Covidien (NYSE: COV) by Medtronic (NYSE: MDT), a deal which turns eyes to Johnson & Johnson (NYSE: JNJ).

"We expect many investors will expect J&J to buy something in the cardiac space," BTIG analyst Sean Lavin said in a research note.

With its latest acquisition, Medtronic becomes the largest player in the cardiac market and second-largest in surgery, Lavin said. Johnson & Johnson remains the biggest in surgery, but with almost nothing in the cardiac segment.

The thinking goes that Johnson & Johnson may acquire either a large cardiac player or a number of smaller ones.

Among shares trading up on the news as predicted by Lavin Monday were St. Jude Medical (NYSE: STJ) up 1.49 percent to $66.06 a share, Boston Scientific (BSX) $12.93, up 1.02 percent, and Abiomed (NASDAQ: ABMD), $23.15, up 0.87 percent.

"It's tough to say which way Intuitive Surgical will go, since this removes Covidien as a potential buyer," Lavin said earlier Monday.

In late afternoon trading, Intuitive Surgical was up 3.33 percent to $410.05 a share.

As for the Medtronic Covidien deal itself, Lavin said the 30 percent premium over Covidien's recent closing price is "highly likely to be accepted" and no further bidders seem likely to emerge.

The deal offers better global presence to Medtronic and better product launch experience to Covidien, Benchmark analyst Jan Wald said in a research note calling the deal "attractive."

Wald cut the rating on Covidien to Hold from Buy, citing the stock's reaction to the merger news.

Similarly, CRT analyst Shagun Singh Chadha called the deal "sufficiently attractive" and boosted a price target for Covidien to $93.22, from $82. Chadha cut the company's rating to Fair Value, from Buy.

New York law firm Levi & Korsinsky threatened a class action suit and said it is investigating whether Covidien breached fiduciary duties "by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Medtronic is underpaying."

Latest Ratings for COV

DateFirmActionFromTo
Nov 2014JefferiesMaintainsBuy
Oct 2014Morgan StanleyDowngradesOverweightEqual-Weight
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for COV
View the Latest Analyst Ratings

 

Related Articles (COV)

View Comments and Join the Discussion!

Posted-In: Benchmark btig CRT Jan WaldAnalyst Color M&A News Analyst Ratings

Latest Ratings

StockFirmActionPT
PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com